500187-46-2Relevant academic research and scientific papers
Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones
Colletti, Steven L.,Frie, Jessica L.,Dixon, Elizabeth C.,Singh, Suresh B.,Choi, Bernard K.,Scapin, Giovanna,Fitzgerald, Catherine E.,Kumar, Sanjeev,Nichols, Elizabeth A.,O'Keefe, Stephen J.,O'Neill, Edward A.,Porter, Gene,Samuel, Koppara,Schmatz, Dennis M.,Schwartz, Cheryl D.,Shoop, Wesley L.,Thompson, Chris M.,Thompson, James E.,Wang, Ruixiu,Woods, Andrea,Zaller, Dennis M.,Doherty, James B.
, p. 349 - 352 (2007/10/03)
Imidazo[1,2-α]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.
